Targeted therapy, erlotinib, nowadays plays an important role in the first-line treatment of advanced non-small cell lung cancer (NSCLC) thanks to its effectiveness. However, its costeffectiveness is still controversial. The aim of the study is to review the available evidence on costeffectiveness of erlotinib in the first-line treatment of advanced NSCLC.
A Systematic Review of Pharmacoeconomic Evaluation of Erlotinib in
The First-Line Treatment of Advanced Non-Small Cell Lung Cancer Nguyen TT, Grappasonni I, Nguyen TB, Petrelli F Objectives Targeted therapy, erlotinib, nowadays plays an important role in the first-line treatment of advanced non-small cell lung cancer (NSCLC) thanks to its effectiveness. However, its costeffectiveness is still controversial. The aim of the study is to review the available evidence on costeffectiveness of erlotinib in the first-line treatment of advanced NSCLC.
Methods
A systematic review was conducted to identify full-text publications in 3 electronic databases (Sciencedirect, Pubmed, Cochrane) from 2000 with key words through MeSH tool. The researches met inclusion criteria (an original economic evaluation of erlotinib in the first-line treatment of advanced NSCLCand written in English) were extracted data and summarized results into prespecified information table. To compare the results of studies, all currency values were transferred into $USD in 2016 based on Consumer Price Index. The report's quality of the studies was assessed via the Quality of Health Economic Studies (QHES) instrument by 3 blinded reviewers.
Results
From a total 94 detected papers, 9 studies were included in the review. 4 studies compared erlotinib with the best supportive care, 2 studies dealt with reverse strategy, the others compared with cisplatin plus pemetrexed, gefitiniband carboplatin plus gemcitabine. Costeffectiveness analysis, modeling and sensitivity analysis were mostly used methods in these studies. All researches evaluated direct costs and used QALY as outcome with 3% discount rate. The ICUR/QALY of studies ranged from dominant to $275,428/QALY. Based on WTP threshold, 7/9 studies concluded that erlotinib was cost-effectiveness, 2 studies comparing erlotinib with reverse strategy did not find the difference in cost-effectiveness. Using QHES tool, it has been shown the high quality of these studies with the mean score of 82.17 (6.85) on a scale of 100.
Conclusions
Most studies suggested that erlotinib was cost-effectiveness in the first-line treatment of advanced NSCLC and the report's quality of studies was high.
